2002 2019 Access DEA 
Cannabis Law Report
JULY 9, 2021
Denver, Colorado was the first jurisdiction to decriminalize the use of psilocybin via ballot initiative in May 2019. Then, in November 2019, the FDA granted the designation to the nonprofit Usona Institute to study psilocybin’s effect on major depressive order, for which clinical trials are currently under way. AIMS Institute, PLLC.
PrestoDoctor
JULY 16, 2019
Additionally, the group has been at the front lines of criminal justice reform and harm reduction, which includes passing numerous regulations and advocating for safe syringe access for opioid addicts. According to plaintiff José Belén, “the DEA was told to act with ‘great dispatch’ and with ‘all deliberate speed”.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
PrestoDoctor
JULY 16, 2019
Additionally, the group has been at the front lines of criminal justice reform and harm reduction, which includes passing numerous regulations and advocating for safe syringe access for opioid addicts. According to plaintiff José Belén, “the DEA was told to act with ‘great dispatch’ and with ‘all deliberate speed”.
Cannabis Law Report
APRIL 8, 2022
Later that year, Doblin sued the DEA for the first time. submitted his first DEA application to manufacture marijuana for use in medical research. To celebrate this, we invite you to take a trip down memory lane and review highlights from every year of our history. Lyle Craker, Ph.D., MAPS Founder Rick Doblin, Ph.D.,
Kind Meds (Cannabis Education Blog)
FEBRUARY 7, 2022
The DEA still classifies cannabis as a Schedule I controlled substance, a designation reserved for drugs with no medical value and a high potential for abuse. The governor of Alabama signed a recreational bill into law in 2021, but patients will likely not have access to retail products until 2022. each year since 2019.
Expert insights. Personalized for you.
105 
Let's personalize your content